The ne­go­ti­a­tions list is here; Am­gen, Hori­zon clear FTC hur­dle; Fall biotech IPOs?; No­vo buys biotech part­ner in obe­si­ty; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

If you get the End­points Week­ly in your email in­box, you may no­tice that we have a new look. Be­tween the se­lec­tion of drugs to go un­der Medicare price ne­go­ti­a­tions and the FTC’s set­tle­ment with Am­gen and Hori­zon, it has been a his­tor­i­cal week with sweep­ing im­pli­ca­tions for bio­phar­ma. And there’s a lot more — see if you missed any ma­jor news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER